Abvc Biopharma (ABVC) Preferred Stock Liabilities (2020)
Abvc Biopharma's (ABVC) quarterly Preferred Stock Liabilities came in at $2.2 million in Q3 2020, up 26.88% quarter-over-quarter from $1.7 million in Q2 2020.
Powered by 
Analysis
Abvc Biopharma (ABVC) Preferred Stock Liabilities (2020) Analysis & Trends
Abvc Biopharma (ABVC) has reported Preferred Stock Liabilities for 1 consecutive years, with $2.2 million the latest figure, recorded in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |